Spots Global Cancer Trial Database for stage iii lip and oral cavity cancer ajcc v8

Every month we try and update this database with for stage iii lip and oral cavity cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation	NCT05512767	Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck C... Stage II Hypoph... Stage II Laryng... Stage II Lip an... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Best Practice Consensus Audit... Diagnostic Imag... Lymphedema Mana... Modified Barium... Nasopharyngeal ... Pneumatic Compr... Quality-of-Life... Questionnaire A... Voice Handicap ...	18 Years -	Mayo Clinic
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer	NCT06084845	Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biospecimen Col... Carboplatin Chest Radiograp... Cisplatin Computed Tomogr... Image Guided Ra... Intensity-Modul... Magnetic Resona... Positron Emissi... Xevinapant	18 Years -	Eastern Cooperative Oncology Group
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT05172245	Clinical Stage ... Head and Neck C... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Maxillary Sinus... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage III Sinon... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph... Stage IVB Sinon...	Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Ipatasertib Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin	NCT04533750	Advanced Head a... Advanced Hypoph... Advanced Laryng... Advanced Oral C... Advanced Oropha... Clinical Stage ... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph...	Computed Tomogr... Fludeoxyglucose... Intensity-Modul... Magnetic Resona... Peposertib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin	NCT04533750	Advanced Head a... Advanced Hypoph... Advanced Laryng... Advanced Oral C... Advanced Oropha... Clinical Stage ... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph...	Computed Tomogr... Fludeoxyglucose... Intensity-Modul... Magnetic Resona... Peposertib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin	NCT03258554	Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Pathologic Stag... Squamous Cell C... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Oroph...	Cetuximab Durvalumab Intensity-Modul... Laboratory Biom... Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation	NCT05512767	Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck C... Stage II Hypoph... Stage II Laryng... Stage II Lip an... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Best Practice Consensus Audit... Diagnostic Imag... Lymphedema Mana... Modified Barium... Nasopharyngeal ... Pneumatic Compr... Quality-of-Life... Questionnaire A... Voice Handicap ...	18 Years -	Mayo Clinic
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	NCT05136196	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	NCT02734537	Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Laryngeal Squam... Lip and Oral Ca... p16INK4a Negati... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oral ... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oral ... Stage IVA Oroph...	Cisplatin Intensity-Modul... Laboratory Biom...	18 Years -	Eastern Cooperative Oncology Group
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	NCT05136196	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer	NCT04576091	Clinical Stage ... Clinical Stage ... Recurrent Cutan... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Recurrent Paran... Recurrent Saliv... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Major... Stage III Oroph... Stage III Sinon... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Major ... Stage IV Oropha... Stage IV Sinona... Unresectable Cu... Unresectable He... Unresectable Hy... Unresectable La... Unresectable Or... Unresectable Or... Unresectable Pa... Unresectable Sa...	Biospecimen Col... Computed Tomogr... Elimusertib Pembrolizumab Positron Emissi... Quality-of-Life... Stereotactic Bo...	18 Years -	National Cancer Institute (NCI)
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	NCT02734537	Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Laryngeal Squam... Lip and Oral Ca... p16INK4a Negati... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oral ... Stage III Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oral ... Stage IVA Oroph...	Cisplatin Intensity-Modul... Laboratory Biom...	18 Years -	Eastern Cooperative Oncology Group
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation	NCT05512767	Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck C... Stage II Hypoph... Stage II Laryng... Stage II Lip an... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Best Practice Consensus Audit... Diagnostic Imag... Lymphedema Mana... Modified Barium... Nasopharyngeal ... Pneumatic Compr... Quality-of-Life... Questionnaire A... Voice Handicap ...	18 Years -	Mayo Clinic
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery	NCT05316688	Oral Cavity Squ... Stage I Lip and... Stage II Lip an... Stage III Lip a... Stage IVA Lip a...	Near Infrared I... Therapeutic Con... Tozuleristide	18 Years -	University of Washington

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: